Skip to content
Screener

Eli Lilly LLY Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$19.8BBeat by $2.0B
EPS$8.55Beat by $1.58
Revenue estimate$17.8B
EPS estimate$6.97
“2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion, A key milestone was the U.S. FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions.”
David A. Ricks

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$22.3B
EPS estimate$9.92

Financials

Q1 2026

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$821.68B+10.8%
Enterprise value$859.77B+10.6%
P/E32.5×-34.3×
P/S11.4×-3.8×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Segments

By product

See full
Mounjaro$8.7B+125%
Zepbound$4.2B+79.9%
Verzenio$1.3B+12.3%
Jardiance$1.1B+9.9%
Other oncology$966.0M+22.4%

By segment

See full
Reportable Segment$19.8B+55.5%

FAQ

When did Eli Lilly report Q1 2026 earnings?
Eli Lilly (LLY) reported Q1 2026 earnings on April 30, 2026 before market open.
What were Eli Lilly's Q1 2026 revenue and EPS?
Eli Lilly reported revenue of $19.8B and eps of $8.55 for Q1 2026.
Did Eli Lilly beat estimates in Q1 2026?
Revenue beat the consensus estimate of $17.8B by $2.0B. EPS beat the consensus estimate of $6.97 by $1.58.
How did Eli Lilly's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 55.5% from $12.7B a year earlier and eps grew 156.0% from $3.34.
Where can I find Eli Lilly's Q1 2026 SEC filings?
You can read the 8-K earnings release (0000059478-26-000043) and the 10-Q periodic report (0000059478-26-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.